To compare the prevalence of metabolic syndrome (MetS) and its components in second-generation antipsychotic (SGA)-treated and SGA-naive children; and to explore the utility of clinical markers, such as waist circumference (WC) and body mass index (BMI), as screening tools for MetS.
Methods:
Subjects were prospectively recruited from the Psychiatry Emergency Unit at British Columbia Children's Hospital. As part of a quality-assurance project, a metabolic monitoring protocol was implemented, including collection of anthropomorphic and laboratory data.
Results:
From January 2008 to February 2010, there were 117 SGA-treated and 217 SGA-naive children recruited. The overall prevalence of MetS was 19.0% (16/84; median treatment duration = 14 months) in SGA-treated and 0.8% (1/127) in SGA-naive children (OR 29.7; 95% CI 3.85 to 228.40, P < 0.001), with an increased prevalence of all components except high-density lipoprotein cholesterol (HDL-C), respectively: elevated WC (40.7% and 10.1%; P < 0.001); hypertriglyceridemia (33.7% and 18.8%; P = 0.01); impaired fasting glucose (12.5% and 0.7%; P = 0.005); and elevated blood pressure (41.2% and 16.5%; P < 0.001). SGA treatment was the strongest predictor of MetS (OR 19.2; 95% CI 2.30 to 160.44, P = 0.006) followed by male sex (OR 5.7; 95% CI 1.08 to 30.62, P = 0.04). Presence of abdominal obesity was more sensitive (92.9%) than BMI (68.8%), while fasting glucose of 5.6 mmol/L or more and HDL-C of 1.03mmol/L or less were most specific (94.1%) in correctly identifying MetS.
Conclusions:
SGA treatment confers a significantly increased risk for MetS over the long term. WC measurement is a simple and sensitive screening tool for determining MetS risk in SGA-treated children. These data highlight the dangers of SGA treatment and the importance of standardized metabolic monitoring using sex- and age-adjusted tables in this population.
OlfsonMBlancoCLiuLNational trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679–685.
2.
Therapeutics Initiative: Evidence Based Drug Therapy. Increasing use of newer antipsychotics in children: A cause for concern? Therapeutics Letter. 2009(74):1–2. The Therapeutics Initiative is a member of the International Society of Drug Bulletins.
3.
PanagiotopoulosCRonsleyRElbeDFirst do no harm: Promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry. 2010;19(2):124–137.
4.
DoeyTHandelmanKSeabrookJASurvey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry. 2007;52(6):363–368.
5.
CorrellCULeuchtSKaneJM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–425.
6.
KaneJM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol. 2001;11(Suppl 4):S397–S403.
7.
TandonRHalbreichU.The second-generation ‘atypical’ antipsychotics: Similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology. 2003;28(Suppl 1):1–7.
8.
MeyerJMKoroCE. The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophr Res. 2004;70(1):1–17.
9.
NasrallahHANewcomerJW. Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24(5 Suppl 1):S7–S14.
10.
WuRRZhaoJPLiuZNEffects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology. 2006;186(4):572–578.
11.
CohenD.Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry. 2004;37(1):1–11.
12.
HendersonDC. Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence?CNS Drugs. 2002;16(2):77–89.
13.
NewcomerJWNasrallahHALoebelAD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: Practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol. 2004;24(5 Suppl 1):S1–S6.
14.
GrundySMCleemanJIDanielsSRDiagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1–6.
15.
LiCFordESHuangTTPatterns of change in cardiometabolic risk factors associated with the metabolic syndrome among children and adolescents: The Fels Longitudinal Study. J Pediatr. 2009;155(3):S5.e9–e16.
16.
AlbertiKGEckelRHGrundySMHarmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645.
17.
BurnsTLLetuchyEMPaulosRChildhood predictors of the metabolic syndrome in middle-aged adults: The Muscatine study. J Pediatr. 2009;155(3):S5.e17–e26.
18.
CookSAuingerPLiCMetabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999–2002. J Pediatr. 2008;152(2):165–170.
19.
ShaibiGQGoranMI. Examining metabolic syndrome definitions in overweight Hispanic youth: A focus on insulin resistance. J Pediatr. 2008;152(2):171–176.
20.
CruzMLGoranMI. The metabolic syndrome in children and adolescents. Curr Diab Rep. 2004;4(1):53–62.
21.
CaseyDE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med. 2005;118(Suppl 2):15S–22S.
22.
CohnTPrud'hommeDStreinerDCharacterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49(11):753–760.
23.
Sicras-MainarABlanca-TamayoMRejas-GutierrezJMetabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: A cross-sectional assessment of a primary health care database. Eur Psychiatry. 2008;23(2):100–108.
24.
HacihamdioğluBOkutanVYozgatYAbdominal obesity is an independent risk factor for increased carotid intima-media thickness in obese children. Turk J Pediatr. 2011;53(1):48–54.
25.
IwashimaSNakagawaYIshikawaTAbdominal obesity is associated with cardiovascular risk in Japanese children and adolescents. J Pediatr Endocrinol Metab. 2011;24(1–2):51–54.
26.
CorrellCUCarlsonHE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45(7):771–791.
27.
CorrellCUManuPOlshanskiyVCardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–1773.
28.
PanagiotopoulosCRonsleyRDavidsonJ.Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can J Psychiatry. 2009;54(11):743–749.
29.
McCarthyHDJarrettKVCrawleyHF. The development of waist circumference percentiles in British children aged 5.0–16.9 y. Eur J Clin Nutr. 2001;55(10):902–907.
30.
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–576.
31.
Centers for Disease Control and Prevention. 2000CDC growth charts: United States [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2009 [cited 2010 Feb 5]. Available from: http://www.cdc.gov/growthcharts/background.htm.
32.
BarlowSE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: Summary report. Pediatrics. 2007;120(Suppl 4):S164–S192.
33.
LorenzoCWilliamsKHuntKJThe National Cholesterol Education Program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30(1):8–13.
34.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007;30(Suppl 1):S42–S47.
35.
FernandezJRReddenDTPietrobelliAWaist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr. 2004;145(4):439–444.
36.
MatthewsDRHoskerJPRudenskiASHomeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.
37.
LeeJMOkumuraMJDavisMMPrevalence and determinants of insulin resistance among US adolescents: A population-based study. Diabetes Care. 2006;29(11):2427–2432.
38.
Denney-WilsonECowellCTOkelyADAssociations between insulin and glucose concentrations and anthropometric measures of fat mass in Australian adolescents. BMC Pediatr. 2010;10:58.
39.
Gonzalez-HeydrichJRachesDWilensTERetrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry. 2003;42(10):1227–1233.
40.
JolliffeCJJanssenI.Distribution of lipoproteins by age and gender in adolescents. Circulation. 2006;114(10):1056–1062.
41.
WeissMPanagiotopoulosCGilesLA naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J Child Adolesc Psychopharmacol. 2009;19(5):575–582.
42.
SugawaraNYasui-FurukoriNSatoYPrevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res. 2010;123(2–3):244–250.
43.
CorrellCUDrussBGLombardoIFindings of a US national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv. 2010;61(9):892–898.
44.
McIntyreRSDanilewitzMLiauwSSBipolar disorder and metabolic syndrome: An international perspective. J Affect Disord. 2010;126(3):366–387.
45.
BauerMLecrubierYSuppesT.Awareness of metabolic concerns in patients with bipolar disorder: A survey of European psychiatrists. Eur Psychiatry. 2008;23(3):169–177.
46.
HasnainMFredricksonSKViewegWVMetabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010;10(3):209–216.
47.
WoodsSW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–667.
48.
American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34(Suppl 1):S11–S61.
49.
StrakerDCorrellCUKramer-GinsbergECost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry. 2005;162(6):1217–1221.
50.
VissersDVanroyCDe MeulenaereAMetabolic syndrome in youth: A cross-sectional school-based survey. Acta Paediatr. 2007;96(12):1809–1813.
51.
CookSWeitzmanMAuingerPPrevalence of a metabolic syndrome phenotype in adolescents: Findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med. 2003;157(8):821–827.
52.
de FerrantiSDGauvreauKLudwigDSPrevalence of the metabolic syndrome in American adolescents: Findings from the Third National Health and Nutrition Examination Survey. Circulation. 2004;110(16):2494–2497.
53.
NelsonRABremerAA. Insulin resistance and metabolic syndrome in the pediatric population. Metab Syndr Relat Disord. 2010;8(1):1–14.
54.
FrancoOHMassaroJMCivilJTrajectories of entering the metabolic syndrome: The Framingham heart study. Circulation. 2009;120(20):1943–1950.
55.
de VegtFDekkerJMJagerARelation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001;285(16):2109–2113.
56.
WagenknechtLELangefeldCDScherzingerALInsulin sensitivity, insulin secretion, and abdominal fat: The Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes. 2003;52(10):2490–2496.
57.
Kelty Mental Health Resource Centre. British Columbia mental health metabolic program for children and youth [Internet]. Vancouver (BC): Kelty Mental Health Resource Centre; [date of publication unknown] [cited 2011 Sep 20]. Available from: http://keltymentalhealth.ca/partner/provincial-mental-health-metabolic-program. Resources tab.
58.
FraguasDMerchan-NaranjoJLaitaPMetabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry. 2008;69(7):1166–1175.
59.
FindlingRLJohnsonJLMcClellanJDouble-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study. J Am Acad Child Adolesc Psychiatry. 2010;49(6):583–594.
